Codexis (NASDAQ:CDXS) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Codexis (NASDAQ:CDXS) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports. The company had revenue of $14.91 million for the quarter, compared to analysts’ expectations of $13.82 million. Codexis had a negative return on equity of 68.09% and a negative net margin of 40.97%.

Here are the key takeaways from Codexis’ conference call:

• Financial flexibility improved: Second-quarter revenue was $14.9 million, while product gross margin rose to 73%; management now expects full-year 2026 gross margin in the high 60s. A recent financing generated approximately $25 million in net proceeds, extending the projected cash runway through 2028.
• ECO Synthesis gained commercial traction: New data on precise phosphorothioate stereochemistry and starterless synthesis generated strong customer interest, with several engagements advancing and one of three CDMO partners entering negotiations for a long-term commercial contract.
• RNA manufacturing scale-up remains on track: Codexis plans to begin construction of its approximately $25 million GMP facility after permitting, advance ECO Synthesis production from hundreds of grams toward 500 grams by year-end and eventually kilogram scale, and support customer IND filings and clinical trials.
• Small-molecule biocatalysis is returning to growth: The business remains profitable and benefits from higher-margin products, four partner drug approvals in 2026, a label expansion, and 15 programs in Phase II or III; management sees potential for high-single-digit long-term growth, although sales can remain lumpy.
• Execution and commercialization risks remain: Revenue declined modestly year over year to $14.9 million, the company continues to post quarterly losses, and its $72 million–$76 million 2026 revenue target requires a significant second-half ramp. ECO Synthesis also still faces technical scale-up, customer adoption and contract-conversion risks.

Codexis Trading Up 8.8%

NASDAQ:CDXS traded up $0.13 during trading hours on Wednesday, reaching $1.61. 621,753 shares of the company were exchanged, compared to its average volume of 1,586,902. The firm has a market cap of $146.34 million, a price-to-earnings ratio of -4.35 and a beta of 2.54. The stock has a 50 day simple moving average of $2.16 and a 200 day simple moving average of $1.98. Codexis has a 52-week low of $0.96 and a 52-week high of $3.87. The company has a debt-to-equity ratio of 0.94, a current ratio of 5.36 and a quick ratio of 5.23.

Trending Headlines about Codexis

Here are the key news stories impacting Codexis this week:

• Positive Sentiment: Q2 results exceeded expectations. Codexis reported revenue of approximately $14.9 million, above the $13.82 million analyst estimate, while its adjusted loss of $0.13 per share was narrower than consensus estimates ranging from $0.14 to $0.17. Codexis Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Management maintained its 2026 outlook. Codexis reiterated full-year revenue guidance of $72 million to $76 million, broadly consistent with the approximately $74.2 million analyst consensus, reducing the risk of a near-term outlook cut. Codexis Outlines 2026 Revenue and GMP Facility Build-Out
• Positive Sentiment: Technology and commercial opportunities continue to develop. The company highlighted advances in its ECO Synthesis® Manufacturing Platform, including enzyme-driven control of siRNA stereoisomers, as well as growth in biocatalysis and potential applications in RNA therapeutic manufacturing. Codexis Q2 2026 Earnings Call Highlights
• Neutral Sentiment: A planned GMP facility build-out could expand capacity but will require substantial investment. Codexis plans to spend roughly $25 million on the facility, which may support future growth while increasing execution and cash-use risks. Codexis GMP Facility Build-Out
• Negative Sentiment: Codexis remains unprofitable. The company posted a quarterly loss, with a negative net margin and negative return on equity, so the earnings beat does not yet represent sustainable profitability. Codexis Reports Second Quarter 2026 Financial Results
• Negative Sentiment: The approximately $25 million equity raise creates dilution. Although the proceeds strengthen Codexis’s balance sheet and help fund expansion, issuing additional shares can reduce existing shareholders’ ownership and weigh on valuation.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in shares of Codexis by 21.9% in the 4th quarter. Russell Investments Group Ltd. now owns 59,051 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 10,608 shares in the last quarter. Deutsche Bank AG boosted its stake in Codexis by 3,021.2% during the 4th quarter. Deutsche Bank AG now owns 51,406 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 49,759 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Codexis in the 3rd quarter worth about $88,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Codexis in the 3rd quarter valued at about $59,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Codexis by 1,922.9% in the 2nd quarter. Osaic Holdings Inc. now owns 20,634 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 19,614 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Analysts Set New Price Targets

CDXS has been the topic of several research analyst reports. Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wall Street Zen cut shares of Codexis from a “buy” rating to a “hold” rating in a research report on Sunday, May 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Codexis in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.00.

Codexis Company Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.